共 166 条
[1]
Shorvon S(2001)Pyrrolidone derivatives Lancet 358 1885-1892
[2]
Patsalos PN(2004)Clinical pharmacokinetics of levetiracetam Clin Pharmacokinet 43 707-724
[3]
Lynch BA(2004)The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci USA 101 9861-9866
[4]
Lambeng N(2011)Levetiracetam reverses synaptic deficits produced by overexpression of SV2A PLoS One 6 e29560-168
[5]
Nocka K(2014)Mechanisms of levetiracetam in the control of status epilepticus and epilepsy Front Neurol 5 11-46
[6]
Nowack A(1999)Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat Epilepsy Res 34 161-384
[7]
Malarkey EB(1996)The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine Clin Pharmacokinet 31 29-1579
[8]
Yao J(1995)Clinical pharmacokinetics of new antiepileptic drugs Pharmacol Ther 67 351-145
[9]
Deshpande LS(2001)Pharmacokinetic study of levetiracetam in children Epilepsia 42 1574-71
[10]
Delorenzo RJ(2004)Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience Seizure 13 142-1660